Tacrolimus for steroid- and OKT3-resistant rejection in kidney recipients.
Kliem
V
V
Abteilung Nephrologie, Medizinische Hochschule Hannover, Hannover, Germany.
Petersen
R
R
Ehlerding
G
G
Schaumann
D
D
Eisenberger
U
U
Koch
K M
KM
Pichlmayr
R
R
Brunkhorst
R
R
D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D011239:Prednisolone / Q000627:therapeutic use; D012189:Retrospective Studies; D013256:Steroids / Q000627:therapeutic use*; D016559:Tacrolimus / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D013256:Steroids; D016572:Cyclosporine; D011239:Prednisolone; D001379:Azathioprine; D016559:Tacrolimus; D008775:Methylprednisolone